GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Cyclically Adjusted PB Ratio

Rosetta Genomics (FRA:RQ1) Cyclically Adjusted PB Ratio : (As of Jun. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rosetta Genomics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rosetta Genomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Cyclically Adjusted PB Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rosetta Genomics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Rosetta Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Cyclically Adjusted PB Ratio falls into.



Rosetta Genomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rosetta Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2017 is calculated as:

For example, Rosetta Genomics's adjusted Book Value per Share data for the three months ended in Jun. 2017 was:

Adj_Book=Book Value per Share/CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=0.378/103.3491*103.3491
=0.378

Current CPI (Jun. 2017) = 103.3491.

Rosetta Genomics Quarterly Data

Book Value per Share CPI Adj_Book
200512 -652.667 83.032 -812.368
200603 0.000 84.298 0.000
200606 0.000 85.606 0.000
200609 0.000 85.606 0.000
200612 511.206 85.142 620.527
200703 1,624.300 86.640 1,937.553
200706 1,508.804 87.906 1,773.869
200709 1,373.422 87.964 1,613.633
200712 980.472 88.616 1,143.478
200803 773.370 90.090 887.195
200806 638.745 92.320 715.050
200809 624.502 92.307 699.208
200812 704.970 88.697 821.422
200903 578.166 89.744 665.814
200906 483.494 91.003 549.087
200909 358.202 91.120 406.278
200912 237.310 91.111 269.185
201003 298.197 91.821 335.636
201006 170.334 91.962 191.426
201009 23.605 92.162 26.470
201012 -40.111 92.474 -44.828
201103 98.082 94.283 107.513
201106 57.228 95.235 62.104
201112 -4.637 95.213 -5.033
201206 13.886 96.819 14.823
201212 31.062 96.871 33.139
201306 25.879 98.518 27.148
201312 19.773 98.326 20.783
201406 15.630 100.560 16.064
201409 0.000 100.428 0.000
201412 12.465 99.070 13.003
201503 0.000 99.621 0.000
201506 14.616 100.684 15.003
201509 12.371 100.392 12.735
201512 10.535 99.792 10.910
201603 8.172 100.470 8.406
201606 6.475 101.688 6.581
201609 4.570 101.861 4.637
201612 2.271 101.863 2.304
201706 0.378 103.349 0.378

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rosetta Genomics  (FRA:RQ1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rosetta Genomics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (FRA:RQ1) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines